COVID-19 trials registries data warehouse

https://clinicaltrials.gov/show/NCT04333732

Michael S. Avidan, MBBCh

Linda Yun, lindayun@wustl.edu (PI email not reported)

2020-04-03

Completed

RCT

Randomized

Adaptive

Blind label

multi-center

Prevention

inclusion criteria volunteers without clinical evidence of covid-19 infection aged 18 years and older. healthcare workers based in a primary, secondary or tertiary healthcare setting with a high risk of developing covid-19 due to their potential exposure to patients with sars-cov-2 infection. must have a mobile phone and access to the internet for data collection purposes. participants who are willing and able to provide informed consent via an electronic consent process. exclusion criteria prior enrollment into other covid-19 interventional prevention or treatment trials (observational trials not excluded). self-reported or diagnosed current infection with sars-cov-2 or previous covid-19 diagnosis. self-reported current acute respiratory infection. concurrent and/or recent involvement in other research or use of the investigational product, a product considered to be equivalent to the investigational product, or any other product that is likely to interfere with the investigational products in this trial used within three months of study enrolment. self-reported known allergies to any of the imps and excipients of the imps and placebo. self-reported presence or history of the conditions listed in the appendices. self-reported current use of medication known to interact with any of the medications listed in the appendices. inability or unwillingness to be followed up for the trial period. for m-m-r ii pregnant women. individuals receiving high dose corticosteroids, other immuno-suppressive drugs, alkylating agents or anti-metabolites. individuals undergoing radiotherapy. any malignant disease either untreated or currently undergoing therapy. history of administration of gammaglobulin or blood transfusions within the previous 3 months. participants with an allergy to the mr (mmr) vaccine or its components, including neomycin. idiopathic thrombocytopenic purpura (itp) untreated tuberculosis prior receipt of any vaccines (licensed or investigational) ≤30 days before enrollment planned receipt of any vaccine other than the study intervention within 30 days before and after the study vaccination (not including the flu vaccination via injection) prior receipt of an investigational or licensed vaccine likely to impact on interpretation of the trial data (e.g. adenovirus vectored vaccines, any coronavirus vaccines). any confirmed or suspected immunosuppressive or immunodeficient state, including untreated hiv infection with a cd4t count <200 /ml asplenia

None

2

Washington University School of Medicine

18

None

Ghana;South Africa;United Kingdom;United States;Zambia

Health workers

N/A

3411

Number of Participants With Symptomatic COVID-19 at 60 Days

None

Phase 3

[{"arm_notes": "", "treatment_id": 2187, "treatment_name": "Placebo", "treatment_type": "Placebo", "pharmacological_treatment": "Placebo"}, {"arm_notes": "No information on dose", "treatment_id": 774, "treatment_name": "Measles mumps rubella vaccine", "treatment_type": "Non covid vaccine", "pharmacological_treatment": "Non covid vaccine"}]